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Abstract
Background: The United States (US) has re-instituted smallpox vaccinations to prepare for an
intentional release of the smallpox virus into the civilian population. In an outbreak, people of all
ages will be vaccinated. To prepare for the impact of large-scale ring and mass vaccinations, we
conducted a systematic review of the complication and mortality risks of smallpox vaccination. We
summarized these risks for post-vaccinial encephalitis, vaccinia necrosum (progressive vaccinia),
eczema vaccinatum, generalized vaccinia, and accidental infection (inadvertant autoinoculation).
Methods: Using a MEDLINE search strategy, we identified 348 articles, of which seven studies met
our inclusion criteria (the number of primary vaccinations and re-vaccinations were reported,
sufficient data were provided to calculate complication or case-fatality risks, and comparable case
definitions were used). For each complication, we estimated of the complication, death, and case-
fatality risks.
Results: The life-threatening complications of post-vaccinial encephalitis and vaccinia necrosum
were at least 3 and 1 per million primary vaccinations, respectively. Twenty-nine percent of
vaccinees with post-vaccinial encephalitis died and 15% with vaccinia necrosum died. There were
no deaths among vaccinees that developed eczema vaccinatum; however, 2.3% of non-vaccinated
contacts with eczema vaccinatum died. Among re-vaccinees, the risk of post-vaccinial encephalitis
was reduced 26-fold, the risk of generalized vaccinia was reduced 29-fold, and the risk of eczema
vaccinatum was reduced 12-fold. However, the risk reductions of accidental infection and vaccinia
necrosum were modest (3.8 and 1.5 fold respectively).
Background
In the United States (US) routine smallpox vaccination of
the general population ended in 1972 [1]. The last known
case of naturally-acquired smallpox occurred in Somalia
in 1977, and in 1980 the World Health Organization
(WHO) declared that smallpox had been eradicated from
the world [2]. Today, most of the US and the world's pop-
ulation is considered susceptible to smallpox infection.
Since the September 2001 airplane attacks on the World
Trade Center and the anthrax spore attacks using the US
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mail, the US has taken several steps to mitigate a possible
intentional release of variola major (smallpox) virus [3–
6], including re-instituting a national smallpox vaccina-
tion program [7]. For Phase 1 of this program, the Advi-
sory Committee on Immunization Practices (ACIP)
recommended voluntary vaccination of 500,000 mem-
bers of public health response and hospital health care
teams [8]. In Phase 2, up to 10 million first responders
such as police, fire, paramedics, and other health care staff
would be offered voluntary smallpox vaccination.
However, the implementation the smallpox vaccination
program is not without controversy [9]. Vaccinating indi-
viduals against smallpox infection, even voluntarily,
means exposing vaccinees and their contacts to the risks of
serious adverse reactions without the clear benefit of pro-
tection against an infection which does not exist and may
never exist again. Volunteers must balance their individ-
ual risks and benefits of smallpox vaccination. The indi-
vidual risks and benefits from being vaccinated before an
intentional release depends on the probability of an
adverse vaccine reaction, the probability that smallpox
virus will be released, and the probability that an individ-
ual would be directly exposed to a release or an unrecog-
nized case of smallpox [10]. Once an outbreak occurs,
ring and mass vaccination would result in a large number
of primary vaccinees of all ages, including some with
underlying or unrecognized risks for vaccine adverse reac-
tions. In this scenario, we would expect to see an increased
number and risk of vaccine complications. Estimation of
the vaccine complication risks by age, including their pre-
cision and estimation biases, are necessary to formulate
policies and inform individual choice regarding the risks
and benefits of pre-outbreak smallpox vaccination, and to
estimate the burden of vaccine complications from ring
and mass vaccination during an smallpox outbreak in the
general population.
Recent publications [11–16] have summarized or cited
the complication risks associated with receiving smallpox
vaccination; however, to our knowledge, no systematic
review of this older literature has been conducted. The
purpose of this systematic review is to review and summa-
rize the age-specific complication and case fatality risks of
post-vaccinial encephalitis, vaccinia necrosum (progres-
sive vaccinia), eczema vaccinatum, generalized vaccinia,
and accidental infection (inadvertant autoinoculation)
from smallpox vaccinations conducted in the US. We
restricted our review to US studies because the New York
City Board of Health vaccinia strain, which was the only
strain used in the US, is the strain in current use by the the
national vaccination program (and will be in the future)
[11].
Methods
Searching
Two reviewers (T.J.A., S.U.) conducted the literature
searches, selection of studies, and data extraction. To iden-
tify potential studies we searched MEDLINE which cov-
ered 1965 through November 2002. We entered the
following search string: ((Smallpox Vaccine/*adverse
effects [MeSH terms] AND "English" [Language]) OR
((Vaccination/*adverse effects [MeSH terms] AND "vac-
cinia" [MeSH terms]) AND "English" [Language])). From
this search result, potentially relevant studies on smallpox
vaccine complications were identified, screened, and
retrieved. The reference lists in all retrieved articles,
including reviews, were evaluated to identify, screen, and
retrieve additional articles not identified in the MEDLINE
search. Selected primary authors were contacted to iden-
tify additional studies we may have missed [17,18]. Based
on this consultation and our inclusion criteria (described
below) we did not pursue articles published before 1965
or from additional US databases.
Selection criteria
All US studies of smallpox vaccine complications were
included for further review. Articles were screened further
based on the following criteria: (1) the number of persons
vaccinated and whether the vaccine complications were
reported by vaccination status; that is, whether it was a
primary vaccination or a re-vaccination, (2) sufficient data
were provided to calculate complication or case-fatality
risks, and (3) one or more vaccination complications were
consistent with case definitions as defined by Neff and
colleagues [19]. Prior to this publication there were no
consistent case definitions of smallpox vaccine complica-
tions. The following summarizes the Neff criteria:
• Encephalitis: post-vaccinial central nervous system
involvement, including separately or in combination, the
following symptoms: meningeal signs, ataxia, muscular
weakness, paralysis, lethargy, coma or convulsions,
• Vaccinia necrosum (progressive vaccinia): spreading
necrosis at the site of the vaccination, with or without
metastatic necrotic lesions occurring elsewhere on the
body,
• Eczema vaccinatum: generalized spread of vaccinial
lesions or local implantation of vaccinia in a person who
has eczema or a past history of eczema,
• Generalized vaccinia: generalized vaccinial lesions, with
no eczema or other pre-existing lesion,
• Accidental infection: vaccinial lesions resulting from
accidental autoinoculation of vaccinia virus in the eye orBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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mouth or on other parts of the body, with no eczema or
other pre-existing skin lesions.
Validity assessment
For this review we did not develop a quality score. Instead,
we collected relevant information that might bias the
complication and case fatality risk estimates from each
article. This included information on the study location,
whether potential vaccinees were screened (e.g., history of
eczema/atopic dermatitis), reporting source of vaccine
complications and deaths (numerators), and source of
numbers of persons vaccinated (denominators). This
information was summarized to help the reader interpret
the findings.
Data abstraction
Data from each article were abstracted separately by the
two primary reviewers. For quality control, two additional
staff independently abstracted the data, and any disagree-
ments were resolved by the primary reviewers.
Study characteristics
The selected studies were published in English. They had
the type and number of vaccine complications, and an
estimate of the number of persons vaccinated. The type
and number of complications came from several sources
which are summarized in Table 1. The number of persons
vaccinated were either known as in the US cohort studies
[20,21], or were estimated using data from US national or
state immunization surveys [19,22–25].
Quantitative data synthesis
Data in all the studies, except the Ratner study, were strat-
ified by vaccination status and by the following age
groups (age <1 year, ages 1 to 4 years, ages 5 to 19 years,
ages 20+ years, and all ages combined). For the Ratner
study [21], data in the age groups "Age 5 to 14" and "Age
15+" were counted in the groups "Age 5 to 19" and "Age
20+," respectively.
For primary vaccinations, and for each complication, the
study risk estimates were stratified by age group and by
study, and combined across age groups and studies. First,
the age-specific risk of each complication was calculated
as the number of reported complications divided by the
number vaccinated for that age group. Second, the age-
specific risk of death from post-vaccinial encephalitis, vac-
cinia necrosum, and eczema vaccinatum was calculated as
the number of deaths from each complication divided by
the number vaccinated for that age group. Third, the age-
specific case fatality risks from post-vaccinial encephalitis,
vaccinia necrosum, and eczema vaccinatum were calcu-
lated as the number of deaths from a specific complica-
tion divided by the number with that specific
complication. For all risk estimates, exact 95% confidence
intervals were calculated based on the binomial distribu-
tion using R, a freely available open source programming
language for statistical computing and graphics [26].
Although contact vaccinia was not the focus of this review,
for non-vaccinees with contact-acquired eczema vaccina-
tum that was reported, we calculated the case fatality risk.
For re-vaccinations, the same risk estimates were calcu-
lated as for primary vaccinations. However, because the
risk of complications was much lower for revaccinations,
the risks estimates were stratified by study only and sum-
marized in one table.
Results
Our search yielded a total of 348 studies: 342 from the
MEDLINE search, 2 from the reference lists review
[27,28], 2 from author communications [29,30], and 2
from our files [27,31]. From this pool, 18 articles of small-
pox vaccination complications were identified for further
review. Using our selection criteria we excluded 11 stud-
ies: 3 did not use the Neff criteria [31–33], 3 did not report
complications by vaccination status [34–36], 3 did not
report the total number of vaccinations by vaccination sta-
tus [27,37,38], and 2 studies' results [39,40] were reported
in another article [25]. The remaining 7 articles form the
basis of this systematic review and represent data from
approximately 13,206,095 primary vaccinations and
18,349,359 re-vaccinations [19–25] (Table 1).
The US studies covered the years 1963, 1967, and 1968.
Five of the 7 studies were period analyses [19,22–25]. For
a period analysis, the number of vaccine complications
for a selected geographic location and period of time were
ascertained from a variety of sources (Table 1, columns 6
and 7). The at-risk population was the number of persons
vaccinated in that location during the same time period.
This number was estimated from a variety of sources
including population-based regional and national surveys
(Table 1, column 8). One study was a prospective cohort
study [21] and the other was a clinic-based retrospective
cohort study [20].
Primary vaccination
Post-vaccinial encephalitis
The risk of post-vaccinial encephalitis (complication risk,
CR), the risk of a post-vaccinial encephalitis death (mor-
tality risk, MR), and the individual risk of dying of post-
vaccinial encephalitis (case fatality risk, CFR) by age group
are displayed in Table 2. The highest risk for developing
post-vaccinial encephalitis was among infants aged <1
year old (risk ratio, 2.80, compared to vaccinees aged 1
year or older). Although the summary risk in this age
group was 6.8 cases per million vaccinations, the 1970
Lane et al. study [25] that prospectively surveyedBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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physicians estimated a much higher risk (CR, 176.5 cases
per million; 95% CI, 36.4–515). The risk in vaccinees
aged >1 year was much lower and did not change with
age.
The summary case fatality risk for post-vaccinial encepha-
litis was highest in infants aged <1 year (CFR, 44.4 deaths
per 100 cases; 95% CI, 13.7–78.8), however, it was not
statistically different from the other age groups (P value =
0.21). For all ages groups, combined there were 11 deaths
among 38 cases of post-vaccinial encephalitis (CFR, 28.9
deaths per 100 cases; 95% CI, 15.4–45.9).
Vaccinia necrosum (progressive vaccinia)
The risk of vaccinia necrosum, the risk of a vaccinia necro-
sum death, and the individual risk of dying from vaccinia
Table 1: Comparison of smallpox vaccination adverse effects studies meeting selection criteria for this systematic review
Study 
and year 
published 
[Ref]
Source Number of 
primary and 
re-vaccinations
Screening 
occurred
Complications Numerator source Denominator 
source
Complication Death
Neff 
1967a 
[19]
United States, 1963 6,239,000
7,775,000
NR PVE, VN, EV, 
GV, AI
Red Cross VIG distribution 
system, CDC, National Survey 
of pediatrician and general 
practitioners
Deaths 
certificates
Estimated by 
National Bureau of 
Census 
Immunization 
Survey
Neff 
1967b 
[22]
United States, 1963 
(North Carolina, 
Rhode Island, 
Washington, 
Wyoming)
298,000
370,000
NR PVE, VN, EV, 
GV, AI
Retrospective physician 
survey, Local health officers, 
Records at major medical 
centers
Death 
certificates
Estimated by 
National Bureau of 
Census 
Immunization 
Survey
Lane 
1969 
[24]
United States, 1968 5,594,000
8,574,000
NR PVE, VN, EV, 
GV, AI
Red Cross VIG distribution 
system, Red Cross consultants, 
State & Territorial 
Epidemiologists, Burroughs-
Wellcome Co., Vaccine 
manufacturers, NCDC 
Encephalitic Surveillance Unit, 
NCDC Viral Exanthems Unit
Death 
certificates
Estimated by 
National Bureau of 
Census 
Immunization 
Survey
Lane 
1970 
[25]
United States, 1968 
(Alabama, Alaska, 
Iowa, Kentucky, 
Maine, Maryland, 
Rhode Island, 
South Carolina, 
Washington, West 
Virginia)
596,000
998,000
NR PVE, VN, EV, 
GV, AI
Prospective physician survey, 
Public health nurse survey (2 
states)
NR Estimated by 
National Bureau of 
Census 
Immunization 
Survey
Mellin 
1970 
[23]
United States, 1968 
(Maryland)
109,000
166,000
NR PVE, VN, EV, 
GV, AI
Medical and chirurgical faculty, 
County health officers, Chief 
pediatricians in general 
hospitals, Red Cross VIG 
distribution system, General 
hospitals, Public health nurses
NR Estimated by 
National Bureau of 
Census 
Immunization 
Survey
Ratner 
1970 
[21]
Puerto Rico, 1967 369,546
465,926
Yesa PVE, VN, EV, 
GV, AI
Physician survey, Immunization 
nurses, University hospital 
dermatologists, Red Cross VIG 
distribution system
NR National smallpox 
vaccination 
campaign
Neff 
1972 
[20]
United States, 1968 
(Baltimore 
pediatric clinic)
549
433
NR PVE, VN, EV, 
GV, AI
Pediatric clinic chart review NR Clinic chart review
NR = Not reported, PVE = post-vaccinial encephalitis, VN = vaccinia necrosum, EV = eczema vaccinatum, GV = generalized vaccinia, AI = accidental 
infection (inadvertant autoinoculation), VIG = Vaccinia immune globulin, NCDC = National Communicable Disease Center. aVaccinations withheld 
from persons aged less than 1 year or greater than 60 years, and persons with acute illness, blood dyscrasia, malignancy, pregnancy, eczema or 
infectious skin disease, eczema in household contacts, steroid therapy, radiation therapy; cerebral damage, or seizure disorder. bWyeth Dryvax 
product licensed and is use during this period [11]BMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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necrosum by age group are displayed in Table 3. The high-
est summary risks for developing vaccinia necrosum were
among vaccinees aged 20 years or older (CR, 5.3 cases per
million; 95% CI, 1.4–13.5). For all ages combined, there
were 13 cases of vaccinia necrosum from over 13 million
vaccinations (CR, 1.0 cases per million; 95% CI, 0.5–1.7)
Almost all cases of vaccinia necrosum occurred in persons
with a previously diagnosed hematopoetic malignancy or
immunodeficiency condition [24].
For all age groups combined, there were 2 deaths among
13 cases of vaccinia necrosum (CFR, 15.4 deaths per 100
cases; 95% CI, 1.9–45.4).
Eczema vaccinatum
The risk of eczema vaccinatum, the risk of a eczema vacci-
natum death, and the individual risk of dying from
eczema vaccinatum by age group are displayed in Table 4.
For all age groups combined, there were 169 cases of
eczema vaccinatum from over 13 million vaccinations
Table 2: Risk of post-vaccinial encephalitis (P.V.E.) and death from primary smallpox vaccinations, Stratified by age and study, 1963–
1968
Age group and 
studies
Number 
vaccinated
P.V.E. No. Deaths No. Risk of complication per 
million (95% C.I.)a
Risk of death per million 
(95% C.I.)a
Case fatality risk per 
hundred (95% C.I.)a
Age <1
Neff 1967a 654,000 1 0 1.5 (0.04, 8.5) 0.0 (0.0, 5.6) 0.0 (0.0, 97.5)
Neff 1967b 31,000 1 0 32.3 (0.8, 180) 0.0 (0.0, 119) 0.0 (0.0, 97.5)
Lane 1969 614,000 4 3 6.5 (1.8, 167) 4.9 (1.0, 14.3) 75.0 (19.4, 99.4)
Lane 1970 17,000 3 1 176.5 (36.4, 515) 58.8 (1.5, 328) 33.3 (0.84, 90.6)
Ratner 1970 1 0 0 n/c n/c n/c n/c n/a n/a
Neff 1972 32 0 0 n/c n/c n/c n/c n/a n/a
Summary 1,316,033 9 4 6.8 (3.1, 13.0) 3.0 (0.8, 7.8) 44.4 (13.7, 78.8)
Age 1 to 4
Neff 1967a 2,973,000 2 1 0.7 (0.08, 2.4) 0.3 (0.008, 1.9) 50.0 (1.3, 98.7)
Neff 1967b 142,000 0 0 0.0 (0.0, 26.0) 0.0 (0.0, 26.0) n/a n/a
Lane 1969 2,733,000 6 0 2.2 (0.8, 4.8) 0.0 (0.0, 1.3) 0.0 (0.0, 45.9)
Lane 1970 317,000 3 0 9.5 (2.0, 27.6) 0.0 (0.0, 11.6) 0.0 (0.0, 70.8)
Ratner 1970 68,002 0 0 0.0 (0.0, 54.2) 0.0 (0.0, 54.2) n/a n/a
Neff 1972 517 0 0 0.0 (0.0, 7110) 0.0 (0.0, 7110) n/a n/a
Summary 6,233,519 11 1 1.8 (0.9, 3.2) 0.2 (0.004, 0.9) 9.1 (0.23, 41.3)
Age 5 to 19
Neff 1967a 2,295,000 8 4 3.5 (1.5, 6.9) 1.7 (0.5, 4.5) 50.0 (15.7, 84.3)
Neff 1967b 110,000 0 0 0.0 (0.0, 33.5) 0.0 (0.0, 33.5) n/a n/a
Lane 1969 1,959,000 5 1 2.6 (0.8, 6.0) 0.5 (0.01, 2.8) 20.0 (0.50, 71.6)
Lane 1970 229,000 2 0 8.7 (1.1, 31.5) 0.0 (0.0, 16.1) 0.0 (0.0, 84.2)
Ratner 1970b 193,721 1 1 5.2 (0.1, 28.8) 5.2 (0.1, 28.8) 100.0 (2.5, 100)
Summary 4,786,721 16 6 3.3 (1.9, 5.4) 1.2 (0.5, 2.7) 37.5 (15.2, 64.6)
Age 20 +
Neff 1967a 317,000 1 0 3.2 (0.1, 17.6) 0.0 (0.0, 11.6) 0.0 (0.0, 97.5)
Neff 1967b 15,000 0 0 0.0 (0.0, 246) 0.0 (0.0, 246) n/a n/a
Lane 1969 288,000 1 0 3.5 (0.1, 19.3) 0.0 (0.0, 12.8) 0.0 (0.0, 97.5)
Lane 1970 33,000 0 0 0.0 (0.0, 112) 0.0 (0.0, 112) n/a n/a
Ratner 1970b 107,822 0 0 0.0 (0.0, 34.2) 0.0 (0.0, 34.2) n/a n/a
Summary 760,822 2 0 2.6 (0.3, 9.5) 0.0 (0.0, 4.8) 0.0 (0.0, 84.2)
All agesc
Neff 1967a 6,239,000 12 5 1.9 (0.2, 3.4) 0.8 (0.3, 1.9) 41.7 (15.2, 72.3)
Neff 1967b 298,000 1 0 3.4 (0.1, 18.7) 0.0 (0.0, 12.2) 0.0 (0.0, 97.5)
Lane 1969 5,594,000 16 4 2.9 (1.6, 4.6) 0.7 (0.2, 1.8) 25.0 (7.3, 52.4)
Lane 1970 596,000 8 1 13.4 (5.8, 26.4) 1.7 (0.04, 9.3) 12.5 (0.3, 52.6)
Mellin 1970 109,000 0 0 0.0 (0.0, 33.8) 0.0 (0.0, 33.8) n/a n/a
Ratner 1970 369,546 1 1 2.7 (0.07, 15.1) 2.7 (0.1, 15.1) 100.0 (2.5, 100)
Neff 1972 549 0 0 0.0 (0.0, 6697) 0.0 (0.0, 6697) n/a n/a
Summary 13,206,095 38 11 2.9 (2.0, 3.9) 0.8 (0.4, 1.5) 28.9 (15.4, 45.9)
n/c = not calculated, n/a = not assessable aRisk and confidence intervals not calculated (n/c) for less that 100 vaccinations. Exact confidence intervals 
based on the binomial distribution. bThe Ratner study age groups, "Age 5 to 14" and "Age 15+", were counted in the Table age groups "Age 5 to 19" 
and "Age 20+", respectively. cAll ages group may includes subjects whose age was unknownBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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(CR, 12.8 cases per 1 million vaccinations; 95% CI, 10.9–
14.9). The summary risks of eczema vaccinatum did not
differ across age groups. However, within age groups, the
highest risks were recorded from the US studies that used
physician surveys to ascertain complications not captured
by other reporting mechanisms [22,25]. In these two stud-
ies, the risks of eczema vaccinatum ranged from 30.3 to
96.8 cases per million vaccinations, and were higher in
infants <1 year, although not statistically significant.
For all age groups combined, there were no deaths among
169 cases of eczema vaccinatum (CFR, 0 deaths per 100
cases; 95% CI, 0.0–2.2). However, among non-vaccinees
that developed eczema vaccinatum after contact transmis-
sion from a recent vaccinee, 3 of 132 cases died (2.3
deaths per 100 cases; 95% CI, 0.5–6.5) [19,22,24,25].
Generalized vaccinia
The risk of generalized vaccinia is displayed in Table 5.
The summary risk of developing generalized vaccinia was
Table 3: Risk of vaccinia necrosum (V.N.) (progressive vaccinia) and death from primary smallpox vaccinations, Stratified by age and 
study, 1963–1968
Age group and 
studies
Number 
vaccinated
V.N. No. Deaths No. Risk of complication per 
million (95% C.I.)a
Risk of death per million 
(95% C.I.)a
Case fatality risk per 
hundred (95% C.I.)a
Age <1
Neff 1967a 654,000 1 0 1.5 (0.04, 8.5) 0.0 (0.0, 5.6) 0.0 (0.0, 97.5)
Neff 1967b 31,000 0 0 0.0 (0.0, 122) 0.0 (0.0, 119.0) n/a n/a
Lane 1969 614,000 0 0 0.0 (0.0, 6.0) 0.0 (0.0, 6.0) n/a n/a
Lane 1970 17,000 0 0 0.0 (0.0, 217) 0.0 (0.0, 217) n/a n/a
Ratner 1970 1 0 0 n/c n/c n/c n/c n/a n/a
Neff 1972 32 0 0 n/c n/c n/c n/c n/a n/a
Summary 1,316,033 1 0 0.8 (0.02, 4.2) 0.0 (0.0, 2.8) 0.0 (0.0, 97.5)
Age 1 to 4
Neff 1967a 2,973,000 1 0 0.3 (0.01, 1.9) 0.0 (0.0, 1.2) 0.0 (0.0, 97.5)
Neff 1967b 142,000 0 0 0.0 (0.0, 26.0) 0.0 (0.0, 26.0) n/a n/a
Lane 1969 2,733,000 1 0 0.4 (0.01, 2.0) 0.0 (0.0, 1.3) 0.0 (0.0, 97.5)
Lane 1970 317,000 1 0 3.2 (0.08, 17.6) 0.0 (0.0, 11.6) 0.0 (0.0, 97.5)
Ratner 1970 68,002 0 0 0.0 (0.0, 54.2) 0.0 (0.0, 54.2) n/a n/a
Neff 1972 517 0 0 0.0 (0.0, 7110) 0.0 (0.0, 7110) n/a n/a
Summary 6,233,519 3 0 0.5 (0.1, 1.4) 0.0 (0.0, 0.6) 0.0 (0.0, 70.8)
Age 5 to 19
Neff 1967a 2,295,000 3 0 1.3 (0.3, 3.8) 0.0 (0.0, 1.6) 0.0 (0.0, 70.6)
Neff 1967b 110,000 0 0 0 (0.0, 33.5) 0.0 (0.0, 33.5) n/a n/a
Lane 1969 1,959,000 2 2 1.0 (0.1, 3.7) 1.0 (0.1, 3.7) 100 (15.8, 100)
Lane 1970 229,000 0 0 0 (0.0, 16.1) 0.0 (0.0, 16.1) n/a n/a
Ratner 1970b 193,721 0 0 0 (0.0, 19.0) 0.0 (0.0, 19.0) n/a n/a
Summary 4,786,721 5 2 1.0 (0.34, 2.44) 0.4 (0.05, 1.5) 40.0 (5.3, 85.3)
Age 20 +
Neff 1967a 317,000 2 0 6.3 (0.8, 22.8) 0.0 (0.0, 11.6) 0.0 (0.0, 84.2)
Neff 1967b 15,000 0 0 0.0 (0.0, 246) 0.0 (0.0, 246) n/a n/a
Lane 1969 288,000 2 0 6.9 (0.8, 25.1) 0.0 (0.0, 12.8) 0.0 (0.0, 84.2)
Lane 1970 33,000 0 0 0.0 (0.0, 112) 0.0 (0.0, 112) n/a n/a
Ratner 1970b 107,822 0 0 0.0 (0.0, 34.2) 0.0 (0.0, 34.2) n/a n/a
Summary 760,822 4 0 5.3 (1.4, 13.5) 0.0 (0.0, 4.8) 0.0 (0.0, 60.2)
All agesc
Neff 1967a 6,239,000 7 0 1.1 (0.4, 2.3) 0.0 (0.0, 0.6) 0.0 (0.0, 41.1)
Neff 1967b 298,000 0 0 0.0 (0.0, 12.4) 0.0 (0.0, 12.4) n/a n/a
Lane 1969 5,594,000 5 2 0.9 (0.3, 2.1) 0.4 (0.04, 1.3) 40.0 (5.3, 85.3)
Lane 1970 596,000 1 0 1.7 (0.04, 9.3) 0.0 (0.0, 6.2) 0.0 (0.0, 97.5
Mellin 1970 109,000 0 0 0.0 (0.0, 33.8) 0.0 (0.0, 33.8) n/a n/a
Ratner 1970 369,546 0 0 0.0 (0.0, 10.0) 0.0 (0.0, 10.0) n/a n/a
Neff 1972 549 0 0 0.0 (0.0, 6697) 0.0 (0.0, 6697) n/a n/a
Summary 13,206,095 13 2 1.0 (0.5, 1.7) 0.2 (0.02, 0.5) 15.4 (1.9, 45.4)
n/c = not calculated, n/a = not assessable aRisk and confidence intervals not calculated (n/c) for less that 100 vaccinations. Exact confidence intervals 
based on the binomial distribution. bThe Ratner study age groups, "Age 5 to 14" and "Age 15+", were counted in the Table age groups "Age 5 to 19" 
and "Age 20+", respectively. cAll ages group includes subjects whose age was unknownBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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highest among infants aged <1 year (103.3 cases per mil-
lion vaccinations; 95% CI, 86.7–122.2). However, within
age groups, the highest risks were recorded from the US
studies that used physician surveys to ascertain complica-
tions not captured by other reporting mechanisms
[22,25]. The complication risks ranged from 133.3 to
1647 cases per million vaccinations and were highest in
infants aged <1 year. The highest risks were reported from
the study that prospectively surveyed physicians [25].
For all age groups combined, there were no deaths among
527 cases of generalized vaccinia (CFR, 0 deaths per 100
cases; 95% CI, 0.0–0.7).
Accidental infection (inadvertent autoinoculation)
The risk of accidental infection is displayed in Table 5. For
all age groups combined, there were 857 cases of acciden-
tal infection from over 13 million vaccinations (CR, 64.9
cases per 1 million vaccinations; 95% CI, 60.6–69.4). The
summary risks of accidental infection did not differ across
age groups. However, within age groups, the highest risks
Table 4: Risk of eczema vaccinatum (E.V.) and death from primary smallpox vaccinations, Stratified by age and study, 1963–1968
Age group and 
studies
Number 
vaccinated
E.V. No. Deaths No. Risk of complication per 
million (95% C.I.)a
Risk of death per million 
(95% C.I.)a
Case fatality risk per 
hundred (95% C.I.)a
Age <1
Neff 1967a 654,000 16 0 24.5 (14.0, 39.7) 0.0 (0.0, 5.6) 0.0 (0.0, 20.6)
Neff 1967b 31,000 3 0 96.8 (20.0, 283) 0.0 (0.0, 119) 0.0 (0.0, 70.8)
Lane 1969 614,000 5 0 8.1 (2.6, 19.0) 0.0 (0.0, 6.0) 0.0 (0.0, 52.2)
Lane 1970 17,000 1 0 58.8 (1.5, 328) 0.0 (0.0, 217) 0.0 (0.0, 97.5)
Ratner 1970 1 0 0 n/c n/c n/c n/c n/a n/a
Neff 1972 32 0 0 n/c n/c n/c n/c n/a n/a
Summary 1,316,033 25 0 19.0 (12.3, 28.0) 0.0 (0.0, 2.8) 0.0 (0.0, 13.7)
Age 1 to 4
Neff 1967a 2,973,000 22 0 7.4 (4.6, 11.2) 0.0 (0.0, 1.2) 0.0 (0.0, 15.4)
Neff 1967b 142,000 9 0 63.4 (29.0, 120) 0.0 (0.0, 26.0) 0.0 (0.0, 33.6)
Lane 1969 2,733,000 31 0 11.3 (7.7, 16.1) 0.0 (0.0, 1.3) 0.0 (0.0, 11.2)
Lane 1970 317,000 14 0 44.2 (24.1, 74.1) 0.0 (0.0, 11.6) 0.0 (0.0, 23.2)
Ratner 1970 68,002 0 0 0.0 (0.0, 54.2) 0.0 (0.0, 54.2) n/a n/a
Neff 1972 517 0 0 0.0 (0.0, 7110) 0.0 (0.0, 7110) n/a n/a
Summary 6,233,519 76 0 12.2 (9.6, 15.3) 0.0 (0.0, 0.6) 0.0 (0.0, 4.7)
Age 5 to 19
Neff 1967a 2,295,000 15 0 6.5 (3.7, 10.8) 0.0 (0.3, 1.6) 0.0 (0.0, 21.8)
Neff 1967b 110,000 8 0 72.7 (31.4, 143) 0.0 (0.3, 33.5) 0.0 (0.0, 36.9)
Lane 1969 1,959,000 14 0 7.1 (3.9, 12.0) 0.0 (0.3, 1.9) 0.0 (0.0, 23.2)
Lane 1970 229,000 8 0 34.9 (15.1, 68.8) 0.0 (0.3, 16.1) 0.0 (0.0, 36.9)
Ratner 1970b 193,721 3 0 15.5 (3.2, 45.3) 0.0 (0.3, 19.0) 0.0 (0.0, 70.8)
Summary 4,786,721 48 0 10.0 (7.4, 13.3) 0.0 (0.0, 0.8) 0.0 (0.0, 7.4)
Age 20 +
Neff 1967a 317,000 1 0 3.2 (0.1, 17.6) 0.0 (0.3, 11.6) 0.0 (0.0, 97.5)
Neff 1967b 15,000 1 0 66.7 (1.7, 371) 0.0 (0.3, 246 0.0 (0.0, 97.5)
Lane 1969 288,000 7 0 24.3 (9.8, 50.1) 0.0 (0.3, 12.8) 0.0 (0.0, 41.0)
Lane 1970 33,000 1 0 30.3 (0.8, 169) 0.0 (0.3, 112 0.0 (0.0, 97.5)
Ratner 1970b 107,822 0 0 0.0 (0.0, 34.2) 0.0 (0.3, 34.2) n/a n/a
Summary 760,822 10 0 13.1 (6.3, 24.2) 0.0 (0.0, 4.8) 0.0 (0.0, 30.8)
All agesc
Neff 1967a 6,239,000 54 0 8.6 (6.5, 11.3) 0.0 (0.0, 0.6) 0.0 (0.0, 6.6)
Neff 1967b 298,000 24 0 80.5 (51.6, 120) 0.0 (0.0, 12.4) 0.0 (0.0, 14.2)
Lane 1969 5,594,000 58 0 10.4 (7.9, 13.4) 0.0 (0.0, 0.7) 0.0 (0.0, 6.2)
Lane 1970 596,000 25 0 41.9 (27.1, 61.9) 0.0 (0.0, 6.2) 0.0 (0.0, 13.7)
Mellin 1970 109,000 5 0 45.9 (14.9, 107) 0.0 (0.0, 33.8) 0.0 (0.0, 52.2)
Ratner 1970 369,546 3 0 8.1 (1.7, 23.7) 0.0 (0.0, 10.0) 0.0 (0.0, 70.8)
Neff 1972 549 0 0 0.0 (0.0, 6697) 0.0 (0.0, 6697) n/a n/a
Summary 13,206,095 169 0 12.8 (10.9, 14.9) 0.0 (0.0, 0.3) 0.0 (0.0, 2.2)
n/c = not calculated, n/a = not assessable aRisk and confidence intervals not calculated (n/c) for less that 100 vaccinations. Exact confidence intervals 
based on the binomial distribution. bThe Ratner study age groups, "Age 5 to 14" and "Age 15+", were counted in the Table age groups "Age 5 to 19" 
and "Age 20+", respectively. cAll ages group includes subjects whose age was unknownBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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were recorded from two US studies: the Lane study [25]
that prospectively surveyed physicians and the Neff pedi-
atric clinic study [20]. In the Lane study, the risk ranged
from 371.2 to 2118 cases per million vaccinations, and
was highest in infants aged <1 year. The Neff study
reported 3 accidental infections from 517 vaccinations in
the age group 1 to 4 years (CR, 5803 cases per million;
95% CI, 1198–16,863).
For all age groups combined, there were no deaths among
857 cases of accidental infection (CFR, 0 deaths per 100
cases; 95% CI, 0.0–0.4).
Table 5: Risk of generalized vaccinia (G.V.) and accidental infection (A.I.) from primary smallpox vaccinations, Stratified by age and 
study, 1963–1968
Generalized vaccinia Accidental infection
Age group and 
studies
Number 
vaccinated
G.V.
No.
Deaths
No.
Risk of complication per 
million (95% C.I.)a
Number 
vaccinated
A.I. No. Deaths 
No.
Risk of complication per 
million (95% C.I.)a
Age <1
Neff 1967a 654,000 52 0 79.5 (59.4, 104) 654,000 7 0 10.7 (4.3, 22.0)
Neff 1967b 31,000 12 0 387.1 (200, 676) n/a n/a n/a n/a n/a
Lane 1969 614,000 43 0 70.0 (50.7, 94.3) 614,000 7 0 11.4 (4.6, 23.5)
Lane 1970 17,000 28 0 1647 (1095, 2380) 17,000 36 0 2117.6 (1484, 2930)
Ratner 1970 1 1 0 n/c n/c 1 0 0 n/c n/c
Neff 1972 32 0 0 n/c n/c 32 0 0 n/c n/c
Summary 1,316,033 136 0 103.3 (86.7, 122.2) 1,285,033 50 0 38.9 (28.9, 51.3)
Age 1 to 4
Neff 1967a 2,973,000 46 0 15.5 (11.3, 20.6) 2,973,000 40 0 13.4 (9.6, 18.3)
Neff 1967b 142,000 24 0 169.0 (108, 251) n/a n/a n/a n/a n/a
Lane 1969 2,733,000 47 0 17.2 (12.6, 22.9) 2,733,000 91 0 33.3 (26.8, 40.9)
Lane 1970 317,000 74 0 233.4 (183, 293) 317,000 183 0 577.3 (497, 667)
Ratner 1970 68,002 6 0 88.2 (32.4, 192) 68,002 3 0 44.1 (9.1, 129)
Neff 1972 517 0 0 0.0 (0.0, 7110) 517 3 0 5802.7 (1198, 16,864)
Summary 6,233,519 197 0 31.6 (27.3, 36.3) 6,091,519 320 0 52.5 (46.9, 58.6)
Age 5 to 19
Neff 1967a 2,295,000 24 0 10.5 (6.7, 15.6) 2,295,000 33 0 14.4 (9.9, 20.2)
Neff 1967b 110,000 17 0 154.5 (90.0, 247) n/a n/a n/a n/a n/a
Lane 1969 1,959,000 25 0 12.8 (8.3, 18.8) 1,959,000 35 0 17.9 (12.4, 24.8)
Lane 1970 229,000 32 0 139.7 (95.6, 197) 229,000 85 0 371.2 (296, 459)
Ratner 1970b 193,721 9 0 46.5 (21.2, 88.2) 193,721 2 0 10.3 (1.2, 37.3)
Summary 4,786,721 107 0 22.4 (18.3, 27.0) 4,676,721 155 0 33.1 (28.1, 38.8)
Age 20 +
Neff 1967a 317,000 6 0 18.9 (6.9, 41.2) 317,000 4 0 12.6 (3.4, 32.3)
Neff 1967b 15,000 2 0 133.3 (16.1, 482) n/a n/a n/a n/a n/a
Lane 1969 288,000 13 0 45.1 (24.0, 77.2) 288,000 4 0 13.9 (3.8, 35.6)
Lane 1970 33,000 7 0 212.1 (85.3, 437) 33,000 20 0 606.1 (370, 936)
Ratner 1970b 107,822 10 0 92.7 (44.5, 171) 107,822 8 0 74.2 (32.0, 146)
Summary 760,822 38 0 49.9 (35.3, 68.6) 745,822 36 0 48.3 (33.8, 66.8)
All agesc
Neff 1967a 6,239,000 130 0 20.8 (17.4, 24.7) 6,239,000 85 0 13.6 (10.9, 16.8)
Neff 1967b 298,000 71 0 238.3 (186.1, 300) 298,000 250 0 838.9 (738, 950)
Lane 1969 5,594,000 131 0 23.4 (19.6, 27.8) 5,594,000 142 0 25.4 (21.4, 23.0)
Lane 1970 596,000 157 0 263.4 (224, 308) 596,000 344 0 577.2 (518, 641)
Mellin 1970 109,000 12 0 110.1 (56.9, 192) 109,000 20 0 183.5 (112, 283)
Ratner 1970 369,546 26 0 70.4 (46.0, 103) 369,546 13 0 35.2 (18.7, 60.1)
Neff 1972 549 0 0 0.0 (0.0, 6697) 549 3 0 5464.5 (1128, 15,885)
Summary 13,206,09
5
527 0 39.9 (36.6, 43.5) 13,206,09
5
857 0 64.9 (60.6, 69.4)
n/c = not calculated, n/a = not available from this study aRisk and confidence intervals not calculated (n/c) for less that 100 vaccinations. Exact 
confidence intervals based on the binomial distribution. bThe Ratner study age groups, "Age 5 to 14" and "Age 15+", were counted in the Table age 
groups "Age 5 to 19" and "Age 20+", respectively. cAll ages group includes subjects whose age was unknownBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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Re-vaccination
For smallpox vaccine re-vaccinations, the risks of develop-
ing specific complications, the risks of a specific
complication death, and the individual risks of dying
from specific complications by age group are displayed in
Table 6. Because the risks were so low compared to pri-
mary vaccination, the risks were not stratified by age
group. Compared to primary vaccinations, the summary
risk of post-vaccinial encephalitis was 26 times lower in
re-vaccinations, vaccinia necrosum was 1.5 times lower,
eczema vaccinatum was 12 times lower, generalized vac-
cinia was 29 times lower, and accidental infection was 3.8
times lower. Only 2 deaths occurred from over 19.5 mil-
lion re-vaccinations (MR, 0.1 deaths per million; 95% CI,
Table 6: Risk of serious complications (S.C.) and death from smallpox re-vaccinations for ages greater than 1, 1963–1968
Complication and studies Number 
vaccinated
S.C.
No.
Deaths
No.
Risk of complication per 
million (95% C.I.)a
Risk of death per million 
(95% C.I.)a
Case fatality risk per 
hundred (95% C.I.)a
Post-vaccinial encephalitis
Neff 1967a 7,775,000 0 0 0.0 (0.0, 0.5) 0.0 (0.0, 0.5) n/a n/a
Neff 1967b 370,000 0 0 0.0 (0.0, 10.0) 0.0 (0.0, 10.0) n/a n/a
Lane 1969 8,574,000 0 0 0.0 (0.0, 0.4) 0.0 (0.0, 0.4) n/a n/a
Lane 1970 998,000 2 0 2.0 (0.2, 7.3) 0.0 (0.0, 3.7) 0.0 (0.0, 84.2)
Mellin 1970 166,000 0 0 0.0 (0.0, 22.2) 0.0 (0.0, 22.2) n/a n/a
Ratner 1970 465,926 0 0 0.0 (0.0, 7.9) 0.0 (0.0, 7.9) n/a n/a
Neff 1972 433 0 0 0.0 (0.0, 8483) 0.0 (0.0, 8483) n/a n/a
Summary 18,349,359 2 0 0.1 (0.01, 0.4) 0.0 (0.0, 0.2) 0.0 (0, 84.2)
Vaccinia necrosum
Neff 1967a 7,775,000 2 0 0.3 (0.03, 0.9) 0.0 (0.0, 0.5) 0.0 (0.0, 84.2)
Neff 1967b 370,000 0 0 0.0 (0.0, 10.0) 0.0 (0.0, 10.0) n/a n/a
Lane 1969 8,574,000 6 2 0.7 (0.3, 1.5) 0.2 (0.03, 0.8) 33.3 (4.3, 77.7)
Lane 1970 998,000 3 0 3.0 (0.6, 8.8) 0.0 (0.0, 3.7) 0.0 (0.0, 70.8)
Mellin 1970 166,000 1 0 6.0 (0.2, 33.6) 0.0 (0.0, 22.2) 0.0 (0.0, 97.5)
Ratner 1970 465,926 0 0 0.0 (0.0, 7.9) 0.0 (0.0, 7.9) n/a n/a
Neff 1972 433 0 0 0.0 (0.0, 8483) 0.0 (0.0, 8483) n/a n/a
Summary 18,349,359 12 2 0.7 (0.3, 1.1) 0.1 (0.01, 0.4) 16.7 (2.1, 48.4)
Eczema vaccinatum
Neff 1967a 7,775,000 3 0 0.4 (0.1, 1.1) 0.0 (0.0, 0.5) 0.0 (0.0, 70.8)
Neff 1967b 370,000 5 0 13.5 (4.4, 31.5) 0.0 (0.0, 10.0) 0.0 (0.0, 52.2)
Lane 1969 8,574,000 8 0 0.9 (0.4, 1.8) 0.0 (0.0, 0.4) 0.0 (0.0, 36.9)
Lane 1970 998,000 3 0 3.0 (0.6, 8.8) 0.0 (0.0, 3.7) 0.0 (0.0, 70.8)
Mellin 1970 166,000 0 0 0.0 (0.0, 22.2) n/a n/a n/a n/a
Ratner 1970 465,926 0 0 0.0 (0.0, 7.9) n/a n/a n/a n/a
Neff 1972 433 0 0 0.0 (0.0, 8483) n/a n/a n/a n/a
Summary 18,349,359 19 0 1.0 (0.6, 1.6) 0.0 (0.0, 0.2) 0.0 (0.0, 17.6)
Generalized vaccinia
Neff 1967a 7,775,000 3 0 0.4 (0.1, 1.1) n/c n/c n/c n/c
Neff 1967b 370,000 1 0 2.7 (0.1, 15.1) n/c n/c n/c n/c
Lane 1969 8,574,000 10 0 1.2 (0.6, 2.1) n/c n/c n/c n/c
Lane 1970 998,000 9 0 9.0 (4.1, 17.1) n/c n/c n/c n/c
Mellin 1970 166,000 1 0 6.0 (0.2, 33.6) n/c n/c n/c n/c
Ratner 1970 465,926 1 0 2.1 (0.05, 12.0) n/c n/c n/c n/c
Neff 1972 433 0 0 0.0 (0.0, 8483) n/a n/a n/a n/a
Summary 18,349,359 25 0 1.4 (0.9, 2.0) n/c n/c n/c n/c
Accidental inoculation
Neff 1967a 7,775,000 8 0 1.0 (0.4, 2.0) n/c n/c n/c n/c
Neff 1967b 370,000 250 0 675.7 (594, 765) n/c n/c n/c n/c
Lane 1969 8,574,000 7 0 0.8 (0.3, 1.7) n/c n/c n/c n/c
Lane 1970 998,000 42 0 42.1 (30.3, 56.9) n/c n/c n/c n/c
Mellin 1970 166,000 3 0 18.1 (3.7, 52.8) n/c n/c n/c n/c
Ratner 1970 465,926 1 0 2.1 (0.05, 12.0) n/c n/c n/c n/c
Neff 1972 433 0 0 0.0 (0.0, 8483) n/a n/a n/a n/a
Summary 18,349,359 311 0 16.9 (15.1, 18.9) n/c n/c n/c n/c
n/a = not assessable, n/c = not calculated aExact confidence intervals based on the binomial distributionBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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0.01–0.4). These two deaths occurred among 12 cases of
vaccinia necrosum (CFR 16.7 deaths per 100 cases; 95%
CI, 2.1–48.4).
Discussion
To our knowledge, this is the first systematic review of the
severe complications of smallpox vaccination in the USA.
In addition to the age-specific complication and mortality
risks, the case fatality risks were summarized. Using
pooled summary measures, for every million primary
vaccinations there were 60 cases of accidental infection,
40 cases generalized vaccinia, 13 cases of eczema vaccina-
tum, 3 cases of post-vaccinial encephalitis, and 1 case of
vaccinia necrosum. However, complications for which
vaccinia immune globulin (VIG) was not used (post-vac-
cinial encephalitis) or not generally required (accidental
infection, generalized vaccinia) were significantly under-
reported because they were not captured by the VIG
distribution program that was used by investigators to
ascertain complications. In contrast, the US studies that
used direct physician surveys [22,25] reported signifi-
cantly higher complication risks. For example, the
number of complications per million primary vaccina-
tions for all ages combined was 13.4 cases of post-vaccin-
ial encephalitis [25], 263.4 cases of generalized vaccinia
[25], and 838.9 cases of accidental infection [22].
The complications with the highest summary case fatality
risks were post-vaccinial encephalitis (CFR, 28.9%) and
vaccinia necrosum (CFR, 15.4%). There were no recorded
deaths among vaccinees from other major complications,
including eczema vaccinatum. Deaths from eczema vacci-
natum were observed only among non-vaccinees that
acquired the disease after contact to a recent vaccinee [38].
Neff et al. reported that contact-acquired eczema vaccina-
tum resulted in 3 (2.3%) deaths among the 132 cases in
the US studies [41]. In contrast, in the United Kingdom
(UK) studies contact-acquired eczema vaccinatum
resulted in 9 (7.9%) deaths among 89 cases; however, the
UK vaccinations occurred in the 1950s using a different
vaccinia strain [29,30].
Compared to primary vaccinees, in re-vaccinees the sum-
mary risk was 26-fold lower for post-vaccinial encephali-
tis, 29-fold lower for generalized vaccinia, 12-fold lower
for eczema vaccinatum, 3.8-fold lower for accidental
infection, and 1.5-fold lower for vaccinia necrosum. Prior
vaccination predicted much lower risks for only 3 of the 5
major complications. Therefore, rather than the risks
being significantly modified by prior vaccination status,
the risk for accidental infection is more likely linked to
behavior (autoinoculation) and the risk of vaccinia necro-
sum is more likely determined by immune status at the
time of vaccination. This is consistent with the observa-
tion that vaccinia necrosum occurred almost exclusively
in vaccinees with an severe cell-mediated immunodefi-
ciency [42].
A strength of this systematic review is that the data were
analyzed and summarized by age groups. The complica-
tion risks from each study, or combined, can be compared
within and across age groups. For example, compared to
vaccinees aged 1 year or older, infants aged <1 year had
higher summary risks of post-vaccinial encephalitis (risk
ratio, 2.80) and generalized vaccinia (risk ratio, 3.14). In
contrast, compared to vaccinees aged <20 years, vaccinees
aged 20 or older had a higher summary risk of vaccinia
necrosum (risk ratio, 7.27).
There are several limitations to this systematic review.
First, the studies reviewed were conducted in the 1960s,
and routine smallpox vaccination in the United States
ended in the early 1970s. Before routine smallpox vacci-
nations ceased, the characteristics of those persons vacci-
nated changed as the vaccination risks became better
known and potential vaccinees were screened (e.g.,
infants aged <1 year, history of eczema). To the extent that
routine screening for risk factors was occurring, this would
have reduced the vaccine complication risks. Only the
Ratner prospective cohort study that was conducted in
1967 was able to report vaccination screening criteria
[21].
Second, the methods for ascertaining vaccine complica-
tions and deaths (i.e., the numerator in the risk estimates)
differed between studies. The number of complications
ascertained increased as the quantity and quality of ascer-
tainment methods increased. For example, the studies
that used direct physician surveys [22,25] recorded more
complications that were less severe (generalized vaccinia,
accidental infection) or for which VIG was not used (post-
vaccinial encephalitis). Therefore, the Lane et al. study
[25] that used a prospective physician survey to enhance
reporting yielded the highest (and likely the most accu-
rate) vaccine complication risks for that study period.
With respect to complications deaths, only 3 studies
[19,22,24] reviewed death certificates for this outcome. So
it is possible that the other studies underestimated deaths
due to vaccine complications.
Third, in the Lane and Neff studies reviewed, the investi-
gators were unable to verify the clinical diagnosis from the
reports of adverse events. For example, generalized non-
viremic rashes were sometimes misclassified as general-
ized vaccinia, possibly resulting in an overestimation of
the risk of generalized vaccinia [17,18].
Fourth, the methods for estimating the number of pri-
mary and repeat vaccinations (i.e., the denominator in
risk estimates) differed between studies. Two studies hadBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/26
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data on the actual number of vaccinations given [20,21],
and in the remaining studies the number of vaccinations
were estimated from national or state immunization sur-
veys [19,22,24,25]. Because the complications evaluated
for this review were infrequent, the complication risk esti-
mates are more sensitive to variability in the numerator
than in the denominator. Therefore, inaccuracies in the
estimations of the populations vaccinated would not
likely account for the observed heterogeneity in risk
estimates.
Fifth, geographical and temporal factors may have influ-
enced the heterogeneity of risk estimates. Pre-vaccination
screening practices and the diagnosis and treatment of
complications differed across regions and changed over
time. Because these sources of bias likely contribute more
to the heterogeneity of risk estimates than random error,
the pooled summary measures presented may not be
appropriate. For example, the Centers for Disease Control
and Prevention (CDC) cite, but do not combine, risks esti-
mates from the two Lane studies [24,25] in their report on
smallpox vaccination and adverse reactions [13] in order
to provide a range of risk estimates. Based on this review,
the CDC approach seems appropriate.
Finally, over the past 40 years many factors have changed
that might have affected these studies and their interpreta-
tion, including the design and conduct of epidemiologic
surveillance studies, the diagnosis and treatment of vac-
cine complications, and a change in the distributions of
risk factors (e.g., atopic dermatitis, immunocompro-
mised) among populations that might undergo vaccina-
tions. In spite of all the study limitations, these are the
best available US studies of sufficient size to estimate the
complication and case fatality risks for each major com-
plication among vaccinees.
This systematic review summarizes the major smallpox
vaccine complication and case fatality risks for predicting
the age-specific burden of vaccine complications in the
event of widespread ring and mass vaccinations. Because
atopic dermatitis and immune compromised states are
more common today than when these studies were con-
ducted [12,43–45], higher vaccine complication rates may
be observed in an outbreak. In comparison, in the current
pre-event smallpox vaccination program, rigorous screen-
ing of almost 500,000 vaccinees has resulted in no cases
of eczema vaccinatum and progressive vaccinia [46,47];
however, very high rates of myopericarditis (about
1:1,700 in civilian vaccinees and 1 per 12,800 in military
vaccinees) and possibly myocardial ischemia have been
observed [48,47,49]. Both potential primary and re-vac-
cinees are at risk for myopericarditis. Similar to post-vac-
cinial encephalitis, there is no screening criteria to reduce
complications rates. For these reasons, and because the
long term effects of myopericarditis are not known, the
ACIP has recommended a "pause" in the USA smallpox
vaccination program until the risks and benefits can be
studied more carefully [50]. Unless there is a smallpox
outbreak, at the current time, the individual risks of pre-
event smallpox vaccination outweigh the potential
benefits.
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